In a significant development, the FDA has paused Moderna’s late-stage trial for its norovirus vaccine following a reported case of Guillain-Barre syndrome, a rare neurological side effect. The investigation continues to determine the linkage, keeping Moderna’s mRNA-1403 vaccine on hold for now.
About the Author
